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RSUME is down-regulated in PanNETs and regulates VEGF through HIF1α in PanNET cells
2
RSUME negatively regulates NF-κB activity by enhancing IκBα SUMOylation
3
RSUME enhances PTEN sumoylation, protein stability and increases its nucleus accumulation
model RSUME is downregualted in PanNETs RSUME is induced during hypoxia RSUME positively regulates HIF1α expression VEGF-A is decreased in RSUME KD cells NFκB regulates VEGF-A mRNA ELISA mRNA ELISA NFkB activity is increased in RSUME knockdown BON1 cells RSUME overexpression inhibits NFκB mRNA ELISA IL8 level is increased in RSUME knockdown BON1 cells
RSUME-KD Scramble
Hypoxia + + --RSUME KD reduces PTEN RSUME and PTEN interacts RSUME enhances PTEN sumoylation and decreases ubiquitination and increase protein stability RSUME increases PTEN nucleus accumulation 
INTRODUCTION:
Pancreatic neuroendocrine tumors are rare and represent only about 1 to 2% of all neoplasias of the pancreas . They derive from hormone producing cells of the pancreas and are correspondingly designated as insulinomas, gastrinomas, VIPomas, glucogoninomas etc. The pathogenesis of this heterogenous family of tumors is largely unknown. RSUME was previously identified as sumoylation enhancer protein to stablize target genes such as HIF1a and IκBα. We found that RSUME is highly expressed in pancreas but loss of expression in PanNETs. Therefore the (patho-) physiological consequence due to RSUME absence was studied using PanNET derived BON1 cells. We found that RSUME knockdown in BON cells led to decrease HIF1α expression and vascular density and increased the liver metastasis tested in an orthotopic tumor model and the molecular mechanisms are partly attribute to decreased PTEN expression and increased NFκB activity.
